Phase 1 study of <scp>ABI</scp> ‐009 ( <i>nab</i> ‐rapamycin) for surgically refractory epilepsy ( <scp>RaSuRE</scp> )
ABI-009 was deemed safe and tolerable in a pediatric cohort with medically and surgically refractory epilepsy, establishing a maximum tolerated dose of 20 mg/m<sup>2</sup> and showing early signs of efficacy.
Authors
- Rosita Thiessen
- Jason S. Hauptman (ORCID: https://orcid.org/0000-0002-2035-9876)
- Stephanie Randle
- Hannah E. Goldstein (ORCID: https://orcid.org/0000-0001-5466-2913)
- Jason Lockrow
- Jani Klein
- Russell P. Saneto (ORCID: https://orcid.org/0000-0002-7250-2347)
- Sarah Leary (ORCID: https://orcid.org/0000-0003-0225-6184)
- Jeffrey G. Ojemann (ORCID: https://orcid.org/0000-0001-7580-8934)
- Erin Sullivan
- Patricia Berry (ORCID: https://orcid.org/0000-0001-8904-2239)
- Koko Hall (ORCID: https://orcid.org/0009-0000-9934-6957)
- Mark S. Wainwright (ORCID: https://orcid.org/0000-0002-4736-7462)
- Ghayda Mirzaa (ORCID: https://orcid.org/0000-0003-2648-7657)
- H.A. Willis (ORCID: https://orcid.org/0009-0003-2943-1971)
- Renee Rivers
Institutions
- Seattle Children's Hospital (US)
- Barrow Neurological Institute (US)
- Johns Hopkins University (US)
- University of Washington (US)
- Seattle Children's Hospital (US)
- Center for Cancer and Blood Disorders (US)
Publication Details
- Journal
- Epilepsia
- Published
- 2025-07-19
- DOI
- https://doi.org/10.1111/epi.18555
- Primary Topic
- Metabolism and Genetic Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00